Effectiveness of a Government-Organized and Hospital-Initiated Treatment for Multidrug-Resistant Tuberculosis Patients-A Retrospective Cohort Study

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chan, Pei Chun ^a   Huang, Su Hua ^a   Yu, Ming Chih ^b   Lee, Shih Wei ^c   Huang, Yi Wen ^d   Chien, Shun Tien ^e   Lee, Jen Jyh ^f  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAO YUAN GENERAL HOSPITAL   (Taiwan)

^d Chang Hua Hospital   (Taiwan)

^e Chest Hospital   (Taiwan)

^f TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PATIENT CODING; RETROSPECTIVE STUDY; SPUTUM ANALYSIS; TAIWAN; TAIWAN MULTIDRUG RESISTANT TUBERCULOSIS CONSORTIUM; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GOVERNMENT; HOSPITALS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84874394770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057719     Document Type: Article

References (25)

1. World Health Organization (2008) Anti-tuberculosis drug resistance in the world: fourth global report. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 2002-2007. Geneva: World Health Organization. 37 p.
2. Taiwan CDC, (2009) Taiwan Tuberculosis Control Report 2009. Available: http://www.cdc.gov.tw/uploads/files/cd38b0db-50f5-40ff-abfe-fd11902c1f0b.pdf. Accessed 2012 May 22.
3. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM, (2009) Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4: e6914 doi:10.1371/journal.pone.0006914.
4. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. Available: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf. Accessed 2012 July 27.
5. Leimane V, Riekstina V, Holtz TH, Zaroyska E, Skripconoka V, et al. (2005) Clinical outcome of individualised treatment of multi-drug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365: 318-326.
6. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563-574.
7. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 28: 980-985.
8. Chiang CY, Enarson DA, Yang SL, Suo J, Lin TP, (2002) The impact of national health insurance on the notification of tuberculosis in Taiwan. Int J Tuberc Lung Dis 6: 974-979.
9. Tsai WC, Kung PT, Khan M, Campbell C, Yang WT, et al. (2010) Effects of pay-for-performance system on tuberculosis default cases control and treatment in Taiwan. J Infect 61: 235-243.
10. Bloss E, Chan PC, Cheng NW, Wang KF, Yang SL, et al. (2012) Evaluation of the role of directly observed therapy (DOT) on treatment outcomes in Taiwan. Int J Tuberc Lung Dis 16: 462-467.
11. Huang SH, Lin CH, Chan PC, Huang ASN, Yang CH, et al. (2009) Introduction of Medical Care System for Multi-drug Resistant Tuberculosis in Taiwan. Taiwan Epidemiology Bulletin 25: 86-95.
12. World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization.
13. Laserson K, Thorpe L, Lemaine V, Weyer K, Mitnick CD, et al. (2005) Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 9: 640-645.
14. Su CT, Huang SH, Yu MC, Lee SW, Huang YN, et al. (2010) Preliminary Report-Effectiveness of Taiwan Multiple Drug Resistance Tuberculosis (TMTC). Taiwan Epidemiology Bulletin 26: 400-415.
15. Kim DH, Kim HJ, Park S-K, Kong SJ, Kim YS, et al. (2008) Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. Am J Respir Crit Care Med 178: 1075-1082.
16. Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, et al. (2011) Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis. 15: 1556-1559.
17. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, et al. (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 36: 584-593.
18. Chiang CY, Caminero JA, Enarson DA, (2009) Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int J Tuberc Lung Dis 13: 548-550.
19. Furin J, Bayona J, Becerra M, Farmer P, Golubkov A, et al. (2011) Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis 15: 1294-1300.
20. Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, et al. (2011) Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci 26: 33-41.
21. Tang S, Zhang Q, Yu J, Liu Y, Sha W, et al. (2011) Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand J Infect Dis. 43: 280-285.
22. Li YH, Tsai WC, Khan M, Yang WT, Lee TF, et al. (2010) The effects of pay-for-performance on tuberculosis treatment in Taiwan. Health Policy Plan 25: 334-341.
23. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, et al. (2010) Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 113-119.
24. Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, et al. (2001) Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 33: 1687-1691.
25. Huang SH, Wang KF, Chan PC, Yang CH, Chen CH, (2012) Evolution of MDR-TB Control Strategy in Taiwan. Taiwan Epidemiology Bulletin 28: 269-278.